Company
SciClone Pharmaceuticals
Headquarters: Shanghai, China
Employees: 890
CEO: Mr. Hong Zhao
Market Cap
HK$11.80 Billion
HKD as of July 1, 2024
US$1.51 Billion
SciClone Pharmaceuticals Categories
China Healthcare BiotechnologyChina Healthcare China Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, a thymalfasin for Injection. Its in-licensed products include Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome; and Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy. The company also sells promotion products on behalf of its business partners. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
SciClone Pharmaceuticals has the following listings and related stock indices.
Stock: HKEX: 6600 wb_incandescent